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ABSTRACT 
Objectives: This study examined the relationship between stress, self-efficacy, self-
medication, and pharmacological neuroenhancement (PNE) in the Swiss general population. 
Methods: Using the largest Swiss Internet panel, a sample of 10,171 employees and students 
(unweighted N = 10,084) aged 15 to 74 years was recruited and asked to complete a self-
administered online survey. The data were weighted for age, sex, and language region to 
provide results that were representative of the Swiss population. Multinomial logistic 
regression models were conducted to identify predictors of pharmacological cognitive 
enhancement (PCE) and pharmacological mood enhancement (PME) over the past year. Two 
self-medication models and an overall model were determined.  Results: Current medical 
treatment for a mental disorder was the best predictor of both PCE and PME use as serious 
self-medication. The overall model revealed that cannabis use, frequent stress, and long-term 
stress were predictors of both PCE and PME, whereas negative stressors and time pressure at 
work did not remain in the final model. Furthermore, past-year PCE with and without PME 
was associated with being male, being a student, and using illegal drugs other than cannabis, 
whereas being female and having low self-efficacy predicted past-year PME only. 
Conclusions: Consideration of the predictor variables identified in this study may help to 
identify the potential PCE and PME users for whom measures to prevent drug abuse and 
manage stress are most appropriate. More specifically, the use of PCE and PME as self-
medication to enhance performance at work or while studying needs further consideration in 
the neuroenhancement debate. 
KEYWORDS: Neuroenhancement, cognitive enhancement, mood enhancement, self-
medication, illegal drug use, mental health 
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1. INTRODUCTION 
Pharmacological neuroenhancement (PNE) refers to the nonmedical use of prescription 
drugs, alcohol, and illegal drugs for the purpose of enhancing cognition, mood, or pro-social 
behavior to improve performance at work or while studying (de Jongh et al., 2008; Maier and 
Schaub, 2015). Nonmedical use of prescription drugs is defined as use without having a 
prescription or use for another purpose than prescribed (Maier and Schaub, 2015). More 
specifically, some people with a mental disorder use their medication in higher doses or 
through a different route of administration than prescribed for the purpose of enhanced 
cognitive performance (Arria et al., 2008; Maier et al., 2013).  
However, the literature most likely focuses on healthy individuals’ nonmedical use of 
prescription stimulants for pharmacological cognitive enhancement (PCE). For the most part, 
the discussions are limited to the question whether the drugs used for PCE affect the cognitive 
processes in users without considering altered emotion sufficiently (Vrecko, 2013). 
Nevertheless, stimulants’ effects are not purely cognitive, but also affective and the 
motivational effects are significantly involved in performance outcomes (Ilieva and Farah, 
2013; Vrecko, 2013). Stimulants’ effect on enhanced motivation might also explain why 
healthy users still perceived an enhanced cognitive function, when no objective cognitive 
enhancing effects were found (Ilieva et al., 2013). Furthermore, potential motivational 
enhancing drug effects are also relevant when considering pharmacological mood 
enhancement (PME) or substance use to cope with stress (de Jongh et al., 2008; Maier and 
Schaub, 2015). 
However, an increasing number of media reports on PNE might generate the 
misperception that PNE is an acceptable means of coping with stress and overwhelming 
demands at work or school (Schleim, 2014; Wolff and Brand, 2013). Lazarus described stress 
as a feeling that arises when professional or academic requirements exceed the personal and 
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social resources that an individual is able to mobilize at a given time (Lazarus, 1989). A 
comprehensive study among German students supported this theory and found an association 
between performance pressure and PNE (Middendorff et al., 2012). A further interesting 
study finding was that one quarter of students experienced with PNE reported cannabis use to 
cope with the study demands (Middendorff et al., 2012).  
Notwithstanding, responses to stress can vary greatly among individuals; the use of 
prescription and recreational drugs for PNE represents only one of many possible 
pharmacological coping strategies (Maier and Schaub, 2015; Park and Iacocca, 2014). 
Moreover, PNE with stimulants is strongly associated with risky health behaviors such as 
illegal drug use (Arria et al., 2008; McCabe et al., 2005). Insufficient coping skills and 
substance abuse in the face of chronic stress might cause mental health problems, and vice 
versa (Mohr et al., 2014). Additionally, individual and situation-specific differences in the 
perception of stress and in coping strategies are related to decisions about whether to engage 
in PNE (Sattler et al., 2014). 
Self-efficacy is the ability to initiate and use successful stress coping strategies (Bandura, 
1977) and mediates the path from stress to illness (Sawatzky et al., 2012). In addition, a study 
found that students with high achievement goals and high self-efficacy performed better than 
their counterparts (Cheng and Chiou, 2010). These findings refer to Bandura's (1986) social 
cognitive theory, which states that attainable goals, self-motivation, and controllable 
outcomes are crucial for self-efficacy and personal development. Once the individuals in these 
studies experienced PNE, they showed lower levels of avoidance self-efficacy because they 
could no longer avoid using illicit stimulants in highly stressful situations (Bavarian et al., 
2013). In other words, they were not confident in their own abilities and the functional use of 
drugs for enhancement purposes even further diminished self-efficacy when performance was 
attributed to the drug effects rather than to one’s own abilities. 
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Responsible self-medication with indicated over-the-counter drugs for self-recognized 
conditions is an important element of self-care that reduces the burden on health care systems 
(WHO, 1998). However, Khantzians' (1997) self-medication hypothesis of addictive disorders 
claims that addicts use alcohol or illegal drugs to change the painful affect states that can 
result in addiction. The nonmedical use of prescription drugs or alcohol and illegal drugs for 
PCE or PME to treat an undesired physical or mental condition represents a form of self-
medication that falls in the middle of the range between healthy self-care and addiction. 
However, the terms nonmedical use or misuse are preferred in the scientific literature, and 
definitions that contain the term “enhancement” arise from the bioethical debate (Racine and 
Forlini, 2008). These technical and optimistic terms increase good performers’ fear of 
inadequacy and distract from the issue of serious self-medication among individuals with a 
mental disorder who use drugs to diminish certain higher-order capacities that cause specific 
symptoms of a disorder (Earp et al., 2014). An example provided by Earpand colleagues 
(2014) is the diminishment of memory to reduce traumatic memories. Another example might 
be diminishment of a certain brain function to reduce rumination in patients suffering from 
depression. Consequently, it often remains unclear whether drug use for cognitive 
enhancement in individuals with an undiagnosed mental disorder, such as ADHD, is self-
treatment or misuse (Peterkin et al., 2011; Rabiner et al., 2009a). Both PCE and PME might 
be considered self-medi ation when healthy individuals use drugs to maintain good 
performance when few resources are available or to improve performance from good to 
excellent or from pathological to normal. Thus, PCE and PME are means of achieving 
specific health or performance goals (Wolff et al., 2014). For the most part, studies of 
academic PCE have focused on PCE as moderate self-medication in terms of the self-
optimization of healthy individuals who suffer from stress (Singh et al., 2014; Wolff and 
Brand, 2013). Research has often excluded individuals with mental disorders to avoid the 
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discussion of where treatment ends and enhancement begins (Barrett et al., 2008; Maslen et 
al., 2014). The use of PCE and PME as serious self-medication to combat symptoms of 
mental disorders or the adverse side effects of medical treatment is prevalent (Kasten, 1999) 
but has not yet been investigated in the neuroenhancement literature. Therefore, the current 
study aimed to investigate factors associated with the use of both moderate self-medication 
and serious self-medication to enhance performance at work or while studying. 
1.1.Current study 
The current study is the first to perform an in-depth analysis of the predictors of two 
different forms of neuroenhancement, namely PCE and PME, based on representative 
national-level estimates. Mental disorders and their associated medical treatments as well as 
different forms of stress and self-efficacy were considered as possible predictors of PCE and 
PME. Taking into account the abovementioned theoretical work, stress and insufficient stress 
coping, other illegal drug use, and impaired mental health were assumed to predict both PCE 
and PME. Moreover, it was assumed that different enhancement intentions are related to 
different predictors. PME with the intention to increase psychological well-being differs from 
the rather competitive intention of PCE (Maier and Schaub, 2015; Schleim, 2014). Finally, 
the following hypotheses were made in terms of a moderate self-medication:  
 past-year PCE and PME are both associated with higher levels of past-year 
stress and long-term stress 
 past-year PCE is associated with time pressure and other  negative professional 
or academic stressors in the past year 
 past-year PCE and PME are both associated with illegal drug use in the past year 
 past-year PME is associated with low self-efficacy  
In addition, the following serious self-medication hypothesis was made: 
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 past-year PCE and PME are both associated with current  medical treatment for 
underlying mental disorders 
The understanding of the predictors of PCE and PME derived from this cross-sectional 
study has important implications for preventive measures and future longitudinal research that 
aims to disentangle the relationships among stress, self-efficacy, mental health, and PCE and 
PME. 
2. METHODS 
2.1.Enrollment procedure and study sample 
Participants were recruited through a national Internet panel. The Internet panel of the 
LINK institute for market and social research in Switzerland includes more than 130,000 
people living in Switzerland who consented to be contacted about online public opinion 
surveys during computer-assisted telephone interviews. The panelists were representative of 
the 15- to 74-year-old population in Switzerland that uses the Internet at least once per week 
for private purposes and is able to answer a questionnaire in German, French, or Italian. In 
March 2013, the LINK institute invited 39,996 panelists to participate in a study about health 
and stress at work and in education, and 18,094 panelists took the survey. Following 
screening for exclusion criteria (currently unemployed and not in education = 3,535), quota 
overflow (n = 2,155), and dropouts (n = 2,320), the final sample size was 10,084. The data 
were weighted for age, sex and language region (weighted N = 10,171). Informed consent was 
obtained from all of the participants who were included in the study. 
2.2.Measures 
A self-administered online survey was used to investigate PCE and PME in Switzerland 
(for survey details see Maier et al., in press). For the present study, only variables containing 
current and past-year indicators of stress, health, and health behaviors were considered. 
2.3.Pharmacological neuroenhancement (PNE) 
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Two principal questions assessed past-year PNE. First, participants who indicated having 
ever used prescription drugs or recreational drugs for cognitive enhancement (PCE) at work 
or while studying were asked, whether use also occurred in the past 12 months. Second, 
participants who indicated having ever used prescription drugs or recreational drugs for mood 
enhancement (PME) at work or while studying were asked whether use also occurred in the 
past 12 months. The following four groups were specified: 1) no PNE in the past 12 months; 
2) past-year PME only; 3) past-year PCE; and 4) both past-year PME and PCE. To provide 
sufficient statistical power for logistic regression analyses performed, groups 3 and 4 were 
merged to one group containing all PCE users with and without additional PCE use.   
2.4.Stress measures 
2.4.1. Frequency of stress. To determine the participants’ frequency of stress experiences in 
the past 12 months, they were asked the following question: “During the past 12 months, how 
often have you felt stressed – never, rarely, sometimes, often, or very often?” This variable 
was modeled using the original Likert format. 
2.4.2. Long-term stress at work or in education. To determine whether the participants had 
experienced long-term stress at work or in education, they were asked the following question: 
“Have you experienced stress at work or in education that persisted over several months? 
(Eurofound, 2010)” The answer format was dichotomous (yes or no). 
2.4.3. Time pressure and negative aspects at work or in education. The participants answered 
seven questions about current stress at work or in education that were analyzed by an 
exploratory factor analysis. The factor analysis revealed two stress scales, which were used as 
potential predictors of PCE and PME. The first scale included two items (α = .76) asking for 
frequency of working or learning at a fast pace and under tight deadlines (Eurofound, 2010; 
Grebner et al., 2010). The items were answered on a 6-point scale (almost never, 
approximately one-quarter of the time, approximately half of the time, approximately three-
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quarters of the time, almost always, and always). The second stress scale included five items 
(α = .67) that measured time-independent negative conditions of the participants’ current 
work and education situations that might be related to adverse health outcomes and PNE. 
Those items asked about the frequency of unclear instructions from supervisors and lecturers, 
the occurrence of unnecessary breaks at work or while studying, the feeling of a lack of 
control at work or while studying, competitive pressure, and the need to show inauthentic 
feelings at work or at school (Eurofound, 2010; Grebner et al., 2010). Each of the five items 
was coded on a 5-point scale (never, rarely, sometimes, often, or very often).  
2.5. Other predictor variables 
2.5.1. Socio-demographic characteristics. The following demographic variables were 
included in the analyses: sex, age (15-24, 25-34, 35-44, 45-54, and 55-74 years), professional 
activity (student, employed full-time, and employed part-time), relationship (none/temporary 
and stable), and the presence of children (< 18 years of age) at home (yes or no). 
2.5.2. Mental health and health behavior. The participants indicated their current health status 
in response to the first question of the 12-Item Short Form Health Survey SF-12 (poor, fair, 
good, very good, and excellent), a survey often used by physicians determine patients’ health. 
Moreover, participants were asked about past and current diagnoses of mental health 
disorders (ADHD, narcolepsy, depression, anxiety disorder, and substance use disorder) that 
are known to be treated with medications that the scientific literature often refers to as 
neuroenhancement drugs (Rabiner et al., 2009b; Sattler et al., 2014). A dichotomous variable 
was used in the analysis to represent the current use of a prescription drug to treat at least one 
of the aforementioned mental disorders (yes or no). Participants who reported undergoing 
medical treatment for a past or current mental disorder were asked whether they had ever used 
their prescribed medication in a manner other than prescribed (e.g., at a higher dose or via a 
different route of administration). Past-year psychoactive substance use was assessed 
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dichotomously for tobacco, alcohol, cannabis, and other illegal drugs (cocaine, MDMA, 
amphetamine, ketamine, and GHB/GBL). 
2.5.3. Self-efficacy. The Generalized Self-Efficacy Scale (GSES) was used to assess the 
strength of the participants’ belief in their ability to respond to novel or difficult situations and 
to cope with a variety of stressors (not at all true, barely true, moderately true, and very true). 
The psychometric characteristics of the GSES are satisfactory when implemented online 
(Schwarzer et al., 1999), and the present study revealed good internal consistency (α  = .86). 
2.6.  Logistic Regression Models 
To evaluate each variable’s ability to predict the outcome (PME or PCE with and without 
PME), initial separate multinomial logistic regression analyses were performed (subsequently 
termed ‘univariate analyses’). Past-year non-users were the reference group for the dependent 
variable. First, all significant univariate socio-demographic predictors were entered in the 
preliminary multivariate model (model 1). Non-significant variables were removed from the 
overall model one at a time. Nagelkerke’s R-square was calculated as a goodness-of-fit 
measure for the multivariate multinomial logistic regression model. In a second model, the 
demographics, stress, and self-efficacy were entered as predictors of PME and PCE with and 
without PME (moderate self-medication, model 2). In model 3 (serious self-medication), the 
demographics and current medical treatment for a mental disorder were entered. Finally, in an 
overall multivariate multinomial logistic regression model all remaining significant predictors 
were included to predict PME and PCE with and without PME (model 4). All quantitative 
analyses were conducted using IBM SPSS Statistics Version 22 (SPSS, Inc., Chicago, IL, 
USA), and p < .05 was set as the significance level. 
3. RESULTS 
Of the study participants, 2.1% (n = 215) reported past-year PNE. Two-thirds of the past-
year PNE users (69.2%) felt frequently or very frequently stressed in the past 12 months, 
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compared with 35.5% of the non-users. Four out of five past-year PNE users (80.7%) reported 
long-term stress at work or in education, whereas half of the non-users (49.3%) reported such 
long-term stress. Whereas the non-users who said they experienced long-term stress reported 
that they were rarely unable to cope with their stress (7.6%), one-quarter of the PNE users 
(22.9%) were never or almost never able to cope with stress at work or in education. To 
further specify the groups of interest, 1.4% (n = 146) reported past-year PME and 0.7% (n = 
69) reported past-year PCE with or without PME.  
The characteristics of the study sample used in the analysis of the two different types of 
past-year PNE are depicted in Table 1. All variables except past-year alcohol use were 
univariate predictors of either past-year PME or past-year PCE with and without PME (Table 
1).  
Results from models 1 – 3 are depicted in Table 2. The demographic predictors (model 1) 
explained 14% of the variance (Nagelkerke’s R2). The moderate self-medication model, 
which included demographics, stress, and self-efficacy (model 2) explained 19% of the 
variance. Frequent stress in the past 12 months and long-term stress at work or in education 
were good predictors of PME and PCE with and without PME, but time pressure at work and 
negative stressors at work were excluded from the model. Self-efficacy predicted past-year 
PME. Finally, the serious self-medication model which included both the demographic 
predictors and current medical treatment for a mental health problem (model 3) explained 
30%. 
The overall prediction model resulting from the multinomial logistic regression (R
2
 = .33) 
is presented in Table 3. Current medical treatment was the strongest predictor of both PME 
and PCE with and without PME. Past-year cannabis use and frequent and long-term stress 
were also predictors of both PME and PCE with and without PME. The past-year use of other 
illegal drugs, being male, being a student, being in a relationship, and living without minor 
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children at home were predictors of PCE with and without PME. Being female and having 
low self-efficacy were predictors of PME only. 
Table 4 presents the prevalence mental disorders according to self-report data of non-
users, PME users, and PCE users with and without PME. The majority of the PME users 
reported being diagnosed with depression, and half of them reported undergoing current 
medical treatment for their disorder. Only a small number of the participants with a mental 
disorder reported that they had ever misused their medication for a purpose other than that for 
which it was prescribed. 
4. DISCUSSION 
This study aimed to identify the predictors of PCE and PME separately to determine 
different user groups using two explanation models that focused on self-medication. The first 
moderate self-medication hypothesis stating that frequent and long-term stress predicts PCE 
and PME was confirmed.  
Surprisingly, the second moderate self-medication hypothesis, that time pressure and 
work-related negative stressors would increase the likelihood of PCE, was rejected. In 
particular, no direct link was found between acute work- or study-related environmental 
stressors and PCE. These stressors seemed manageable and were not predictors of PCE and 
PME, whereas frequent and long-term stress and currently impaired mental health were more 
likely to predict drug use for PCE and PME. No matter whether PCE is considered as a 
coping strategy for stress or as part of a certain planning strategy of users, PCE use seems to 
occur most likely when no other effective alternative is promising for lasting changes of a 
somehow uncomfortable situation. As intermittent stress is sometimes resolved automatically, 
it might be less associated with finding new strategies to cope with, such as PCE, or with 
changing the planning behavior. However, our data rely on self-report and perceived stress 
can vary strongly between individuals depending on the cognitive appraisal of stress (Lazarus, 
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1984). Moreover, PCE might be perceived as a short-term solution to reduce long-term stress 
in people with insufficient personal and social resources required to meet certain demands in 
the long-term. This is in line with the finding that students who reported having used drugs to 
improve performance while studying had difficulties to meet the study demands and 
perceived persistently high performance pressure (Maier et al., 2013; Middendorff et al., 
2012). Moreover, pronounced procrastination and high cognitive test anxiety, both 
characteristics that support chronic stress, increased the willingness to use drugs for PCE 
among students (Sattler et al., 2014). 
Consistent with previous studies, the present findings support the third moderate self-
medication hypothesis that PCE and PME are associated with illegal drug use (Arria et al., 
2008; McCabe et al., 2005). Cannabis users were three times more likely to report PCE and 
five times more likely to report PME. A recent longitudinal study showed the strong link 
between cannabis use and mood disorders and suggested that cannabis was used as self-
medication, similar to the definition of PME in the present study (Feingold et al., 2014). The 
use of illegal drugs other than cannabis was positively associated with PCE but not with PME. 
This finding might be explained by the presence of male participants with high levels of 
sensation seeking in the group (Rabiner et al., 2009a). Additionally, individuals with a history 
of illegal drug use might be less afraid of the unknown effects and side effects of prescription 
drugs used for PCE because they are generally used to deal with the uncertainty regarding 
effects and side effects. However, they might even be more likely to use illegal drugs they 
usually use recreationally also for cognitive or mood enhancement. This would then question 
the inclusion of past-year illegal substance use as predictor variable in our model. 
Nevertheless, when considering the low number of illegal drug users reported having ever 
used the illegal drug for direct cognitive or mood enhancement (Table 6 in Maier et al., in 
press), the inclusion is supposed to be accurate. Importantly, alcohol and cannabis use to relax 
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after stress at work or in education was far more prevalent (Maier et al., in press). This is 
consistent with the finding of Middendorff and colleagues (2012) whose study revealed that 
one quarter of PNE users used cannabis to cope with the study demands. However, cannabis 
users in the present study had most likely not thought about cannabis as a drug used for PNE. 
The present findings supported the most specific moderate self-medication hypothesis 
that low self-efficacy would predict PME. Being female and having low self-efficacy were 
predictors of PME. 
Furthermore, the serious self-medication hypothesis was confirmed in the analysis, and 
current medical treatment for a mental disorder, particularly depression and/or an anxiety 
disorder, was the strongest predictor of both PCE and PME. However, misuse of the treatment 
medication among patients was rare, and they used illicit substances for PCE or PME in 
addition to the existing medications to cope with stress and other psychological consequences 
of their disorders. Medical treatment might be perceived as helpful and effective for coping 
with the symptoms of the underlying disorder. Hence, the patients might have learned that 
drugs influence their health outcomes in a positive way, consequently engaging in serious 
self-medication to enhance their performance at work or while studying.  
The present findings are in line with Lazarus' (1989) stress theory; PCE and PME are 
suggested to be stress management strategies for coping with high levels of stress. Consistent 
with previous research, insufficient coping is assumed to be associated with mental health 
problems despite or as a consequence of moderate self-medication in healthy individuals 
(Mohr et al., 2014). Moreover, the fact that PCE and PME were frequently used as serious 
self-medication in addition to current medical treatment provides a new perspective on the 
biomedical ethics debate about PNE. If the target group are not solely healthy people aiming 
to enhance their performance at work or while studying but also people with mental deficits 
aiming to perform normal, the impact of PNE on inequalities might differ. In particular, 
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inequality concerns and questions about the possible exacerbation of existing socio-economic 
inequalities have been raised (Maslen et al., 2014). However, what if people with a mental 
disorder engage in PNE to reduce the stress and symptoms associated with their disorder and 
thus enable themselves to perform at a level equal to that of their healthy counterparts? Given 
that no safe, effective, and highly priced drug for PNE enters the market, the drugs currently 
discussed as neuroenhancers are available relatively equally to all socio-economic groups. 
Earp and colleagues (2014) argued that diminishment can be seen as a form of enhancement. 
Therefore, drug use to diminish certain higher-order capacities that cause the symptoms of a 
mental disorder can be classified as PNE and is a serious self-medication unless it is 
recommended by a physician. Inevitably, normative questions would need to be used to 
define a cut-off point on the continuum between health and disease. However, such a cut-off 
point does not exist and would not be able to sufficiently take into consideration cultural 
differences in the concept of health and illness across and even within countries (Laungani, 
2007). The absence of this clear cut-off point (Maslen et al., 2014), the individual differences 
in responses to drugs used for PNE (de Jongh et al., 2008), and the fact that people might 
obtain the desired prescription or illegal drug from physicians, friends, or via the Internet 
makes it difficult to legally regulate drug use for enhancement purposes. Maslen and 
colleagues (2014) suggest that no unambiguous differentiation between treatment and 
enhancement exists in the vast majority of cases. Therefore, self-medication with PCE and 
PME is also an unsolved issue that needs further consideration. If the bioethical debate is to 
be moved forward, a better understanding of the strong link between mental health and the 
non-competitive interests of PCE and PME users needs to be developed. 
The few healthy PCE users who were identified showed self-efficacy scale values that 
were similar to or even higher than those of non-users. For those users, PCE seems to be a 
lifestyle choice, as Racine and Forlini suggest (2008). PCE users appear to be conscious of 
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their abilities and, in line with the drug instrumentalization theory (Wolff and Brand, 2013), 
they use the desirable functionalities of psychoactive substances as an additional resource.  
Returning to the hypothesis that was posed at the beginning of the study, the findings 
revealed that both PCE and PME were associated with stress. An unanticipated finding was 
that time pressure and negative work aspects were not predictors of PCE and PME in the 
overall model. Only long-term stress and frequent stress predicted PCE and PME. 
Furthermore, the high prevalence of past-year cannabis use in the PCE and PME users 
demonstrated that such drug use is likely to be their stress management strategy and a form of 
moderate self-medication. 
First, this study is one of the largest studies of pharmacological neuroenhancement, and 
the weighting procedures used ensured that the results were representative of the Swiss 
population. Second, participants with a current or past diagnosis of a mental disorder were 
included in the study, whereas many previous studies only focused on healthy individuals 
(Barrett et al., 2008). The important mechanism of self-medication in both healthy and PCE 
and PME users with mental disorders was unique and progressive. Given that the healthy PCE 
users in most previous studies were almost all students, the present investigation was the first 
to consider deficits in PME users in the general population.  
The main limitation of the current study is its cross-sectional design, which did not allow 
the causal associations between the predictors to be conclusively examined. However, the 
self-medication hypothesis was supported, which allowed the interpretation of the findings. A 
further limitation is that the PCE users and the participants who reported both PCE and PME 
were modeled within one single group to increase the statistical power and strengthen the 
prediction models. However, the PCE group is the most commonly studied group (Maier and 
Schaub, 2015; Maslen et al., 2014); therefore, this grouping seems acceptable. Furthermore, 
regular PCE users show a very specific personality profile (Maier et al., 2015), hence it makes 
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sense to compare this group with nonusers and PME users only. The present study assessed 
stress at work and in education as possible predictors of PNE. Because of the length of the 
questionnaire, only single items (no validated scales) were used to assess stress to prevent 
participant dropouts. Retrospectively, the inclusion of at least one validated stress scale may 
have increased the predictive power of the overall model.  
The understanding of PCE and PME as self-medication and as functional means of 
achieving certain ends related to performance or health, as Wolff et al. (2014) suggest, has 
important implications for further research and policy. The findings of the present study 
indicate a large gap between healthy, self-confident PNE users experiencing temporary stress 
and unconfident PNE users with persistently low self-efficacy and high stress or even 
pathological symptoms. Consistent with previous Swiss studies of PNE, only a small number 
of healthy people who reported PNE and recreational drug use as a lifestyle choice were 
found (Maier et al., 2013). Thus, future research should focus on complex problems in 
disadvantaged individuals (e.g., those with low self-efficacy, insufficient coping strategies, or 
mental disorders) who self-medicate without or beyond an indicated prescription. A careful 
diagnosis of mental health disorders, dialogue about treatment options, and investigation of 
social pressure to perform (e.g., in accordance with the perceived averages of healthy 
colleagues) might prevent PCE and PME among patients. The communication of risks and 
medication interactions is strongly recommended to achieve beneficial treatment outcomes 
regarding the absence of additional serious self-medication. 
Various predictor variables for PCE and PME were identified in this study. Consideration 
of these variables may help identifying potential PCE and PME users for whom measures to 
prevent drug abuse and manage stress are most appropriate. Furthermore, causal theories 
concerning engagement in PCE and PME might be examined in longitudinal studies taking 
into account the identified predictors. Especially serious self-medication but also moderate 
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self-medication seem to be suitable candidates for disentangling causal explanations for 
engagement in PCE and PME and thus advancing the neuroenhancement debate.  
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Table 1  
Characteristics of the study population with and without current PNE (12 months) and the univariate 
multinomial associations of each variable with PME only and PCE with or without PME (reference group: no 
PCE/PME during the past 12 months [no current PNE]) 
 
No current PNE PME only,  
12 months 
PCE with and without PME,  
12 months 
 
n = 9,956 n = 146 OR (95%CI) n = 69 OR (95%CI) 
Sex  
    
Male (Ref.) 98.2% (5,335) 1.0% (56) 
 
0.8% (42) 
 
Female 97.5% (4,621) 1.9% (90) 
1.86 (1.33-
2.60)** 
0.6% (27) 0.74 (0.46-1.21) 
Age in years  
    15-24 (Ref.) 96.7% (1,814) 1.8% (33) 
 
1.6% (30) 
 
25-34  98.1% (2,104) 1.2% (25) 0.66 (0.39-1.12) 0.7% (15) 
0.42 (0.23-
0.79)** 
35-44  98.0% (2,206) 1.6% (37) 0.92 (0.57-1.47) 0.4% (8) 
0.22 (0.10-
0.48)** 
45-54  98.2% (2,377) 1.4% (34) 0.79 (0.49-1.28) 0.4% (9) 
0.24 (0.12-
0.50)** 
55-74  98.4% (1,454) 1.1% (17) 0.64 (0.35-1.15) 0.5% (7) 
0.30 (0.13-
0.68)** 
Professional activity  
    Student (Ref.) 96.1% (1,321) 1.8% (25) 
 
2.1% (28) 
 
Full-time work  
≥ 90% 
98.4% (5,456) 1.2% (67) 0.64 (0.41-1.02) 0.4% (21) 
0.18 (0.10-
0.31)** 
Part-time work  
< 90% 
97.7% (3,169) 1.7% (54) 0.90 (0.56-1.45) 0.6% (19) 
0.28 (0.16-
0.50)** 
Relationship      
None / temporary 
(Ref.) 
97.0% (2,703) 2.2% (62)  0.8% (23)  
Stable 98.2% (7,252) 1.1% (85) 
0.51 (0.37-
0.71)** 
0.6% (46) 0.75 (0.46-1.25) 
Children in the 
household 
     
None (Ref.) 97.5% (6,371) 1.6% (105)  0.9% (58)  
At least one <18 
years old  
98.6% (3,585) 1.1% (41) 0.69 (0.48-1.00)* 0.3% (11) 
0.32 (0.17-
0.62)** 
Drug use past 
12 months 
     
No tobacco (Ref.) 98.4% (6,799) 1.1% (78)  0.4% (30)  
Tobacco 96.7% (3,157) 2.1% (68) 
1.89 (1.36-
2.62)** 
1.2% (39) 
2.77 (1.71-
4.47)** 
No alcohol (Ref.) 97.7% (966) 1.4% (13)  0.9% (9)  
Alcohol 97.9% (8,990) 1.4% (133) 1.07 (0.61-1.88) 0.6% (59) 0.69 (0.34-1.38) 
No cannabis (Ref.) 98.3% (9,248) 1.2% (114)  0.5% (47)  
Cannabis 92.9% (708) 4.2% (32) 
3.68 (2.47-
5.48)** 
2.9% (22) 
6.12 (3.66-
10.21)** 
No other illegal 
drugs (Ref.) 
98.0% (9,848) 1.4% (142)  0.5% (54)  
Other illegal drugs
 a
 85.1% (108) 3.3% (4) 2.69 (1.00- 11.6% (15) 24.84 (13.53-
Table
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7.25)** 45.60)** 
Stress       
Not long-term 
(Ref.) 
99.2% (5,049) 0.5% (26)  0.3% (16)  
Long-term  96.6% (4,907) 2.4% (120) 
4.81 (3.14-
7.37)** 
1.0% (53) 
3.45 (1.97-
6.06)** 
Frequency 12 
months                  
scale 1-5 
3.2 (0.9) 4.1 (0.9) 
2.89 (2.38-
3.51)** 
3.9 (1.0) 
2.12 (1.63-
2.76)** 
Time pressure                
scale 1-6 
3.2 (1.2) 3.6 (1.2) 
1.30 (1.14-
1.48)** 
3.5 (1.2) 
1.21 (1.00-
1.46)* 
Negative aspects 
scale 1-5 
2.4 (0.6) 2.7 (0.7) 
2.16 (1.70-
2.73)** 
2.6 (0.7) 
1.90 (1.34-
2.69)** 
Self-efficacy           
scale 10-40 
30.0 (4.1) 27.0 (0.7) 
0.86 (0.83-
0.89)** 
28.1 (5.9) 
0.90 (0.86-
0.95)** 
Perceived health         
scale 1-5 
3.5 (0.8) 2.8 (0.9) 
0.33 (0.27-
0.41)** 
3.0 (0.9) 
0.45 (0.33-
0.61)** 
Current medical 
treatment for a 
mental disorder
 b
 
     
No 98.9% (9,665) 0.7% (65)  0.4% (39)  
Yes 72.4% (291) 20.3% (81) 
41.71 (29.49-
58.99)** 
7.4% (30) 
25.06 (15.33-
40.96)** 
Note. Data are % (n) or mean (SD). PCE = pharmacological cognitive enhancement; PME = pharmacological 
mood enhancement; PNE = pharmacological neuroenhancement.  
a
 Cocaine, ecstasy (MDMA), amphetamines (speed), ketamine, GHB/GBL 
b
 ADHD, narcolepsy, depression, anxiety disorder, dependency 
* p < 0.05; **p < 0.01 
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Table 2   
Multiple prediction models for PME and PCE with and without PME in the past 12 months (reference group: no 
PME/PCE in the past 12 months) 
 
PME only,  
12 months 
n = 146 
OR (95%CI) 
PCE with and without PME, 
12 months 
n = 69 
OR (95%CI) 
Model 1 (socio-demographic data) 
  Sex 
  
Male (Ref.) 
  Female 1.69 (1.17-2.45)** 0.52 (0.30-0.89)* 
Professional activity 
  
Student (Ref.) 
  Full-time work  
≥ 90% 1.15 (0.67-1.97) 0.37 (0.19-0.71)** 
Part-time work  
< 90% 0.99 (0.59-1.64) 0.14 (0.07-0.27)** 
Relationship   
None/temporary (Ref.)   
Stable 0.61 (0.42-0.87)** 1.99 (1.12-3.54)* 
Children in the household   
None (Ref.)   
At least one <18 years old  0.91 (0.61-1.34) 0.41 (0.20-0.83)* 
Drug use past 12 months   
No cannabis (Ref.)   
Cannabis  3.54 (2.28-5.49)** 1.94 (1.02-3.70)* 
No other illegal drugs (Ref.)   
Other illegal drugs
 a
 1.14 (0.40-3.24) 15.47 (7.26-33.00)** 
Perceived health scale 1-5 0.34 (0.28-0.43)** 0.42 (0.31-0.58)** 
Model 2 (moderate self-medication)   
Socio-demographic data (model 1)   
Stress    
Not long-term (Ref.)   
Long-term 2.00 (1.24-3.19)** 1.98 (1.04-3.76)* 
Frequency 12 months, scale 1-5 1.81 (1.45-2.27)** 1.54 (1.13-2.11)** 
Self-efficacy, scale 10-40 0.92 (0.88-0.95)** 0.96 (0.90-1.02) 
Model 3 (serious self-medication)   
Socio-demographic data (model 1)   
Current medical treatment for a mental disorder
 b
   
No   
Yes 32.77 (22.20-48.38)** 24.91 (13.76-45.09)** 
Note. N = 10,171. Model 1 R
2
 = .03 (Cox & Snell), .14 (Nagelkerke). Model χ2 (16) = 296.898, p < .001; Model 
2 R
2
 = .04 (Cox & Snell), .19 (Nagelkerke). Model χ2 (22) = 409.561, p < .001; Model 3 R2 = .06 (Cox & Snell), 
.30 (Nagelkerke). Model χ2 (18) = 656.208, p < .001; PCE = pharmacological cognitive enhancement; PME = 
pharmacological mood enhancement. 
a
 Cocaine, ecstasy (MDMA), amphetamines (speed), ketamine, GHB/GBL 
b
 ADHD, narcolepsy, depression, anxiety disorder, dependency 
* p < 0.05; **p < 0.01 
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Table 3   
Overall multiple prediction model for PME and PCE with and without PME in the past 12 months (reference 
group: no PME/PCE in the past 12 months) 
 
PME only,  
12 months 
n = 146 
OR (95%CI) 
PCE with and without PME, 
12months 
n = 69 
OR (95%CI) 
Sex 
  
Male (Ref.) 
  Female 1.58 (1.06-2.36)* 0.51 (0.29-0.89)* 
Professional activity 
  
Student (Ref.) 
  Full-time work  
≥ 90% 1.17 (0.68-2.01) 0.16 (0.08-0.32)** 
Part-time work  
< 90% 0.95 (0.53-1.71) 0.28 (0.13-0.57)** 
Relationship   
None/temporary (Ref.)   
Stable 0.71 (0.47-1.05) 2.30 (1.26-4.17)** 
Children in the household   
None (Ref.)   
At least one <18 years old   0.89 (0.58-1.36) 0.38 (0.19-0.78)** 
Drug use 12 months   
No cannabis (Ref.)   
Cannabis  4.73 (2.89-7.23)** 2.86 (1.48-5.52)** 
No other illegal drugs (Ref.)   
Other illegal drugs
 a
 1.01 (0.33-3.12) 11.99 (5.48-26.22)** 
Stress    
Not long-term (Ref.)   
Long-term 2.03 (1.24-3.31)** 2.12 (1.10-4.07)* 
Frequency 12 months, scale 1-5 1.61 (1.28-2.02)** 1.43 (1.06-1.94)* 
Self-efficacy, scale 10-40 0.93 (0.90-0.97)** 0.98 (0.93-1.04) 
Current medical treatment for a mental disorder
 b
   
No   
Yes 27.64 (18.78-40.68)** 23.17 (12.91-41.58)** 
Note. N = 10,171. R
2
 = .07 (Cox & Snell), .33 (Nagelkerke). Model χ2 (22) = 708.669, p < .001; PCE = 
pharmacological cognitive enhancement; PME = pharmacological mood enhancement; PNE = pharmacological 
neuroenhancement. 
a
 Cocaine, ecstasy (MDMA), amphetamines (speed), ketamine, GHB/GBL 
b
 ADHD, narcolepsy, depression, anxiety disorder, dependency 
* p < 0.05; **p < 0.01 
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Table 4 
Lifetime prevalence of specified mental disorders and associated medical treatment and medication misuse 
across study groups 
 
No current PNE 
 
 
n = 9,956 
PME only,  
12 months 
 
n = 146 
PCE with and 
without PME,  
12 months 
n = 69 
Depression  
  Lifetime diagnosis 12.0% (1,194) 72.2% (106) 55.1% (38) 
Received medical treatment 8.0% (796) 70.4% (103) 44.4% (31) 
Current medical treatment 2.2% (221) 51.9% (76) 29.6% (20) 
Ever misused 0.3% (33) 6.2% (9) 10.9% (7) 
ADHD    
Lifetime diagnosis 1.7% (174) 6.0% (9) 28.6% (20) 
Received medical treatment 0.6% (62) 2.6% (4) 19.1% (13) 
Current medical treatment 0.2% (22) 0 15.9% (11) 
Ever misused 0.1% (7) 0.9% (1) 4.4% (3) 
Anxiety disorder    
Lifetime diagnosis 8.3% (822) 42.7% (62) 24.4% (17) 
Received medical treatment 3.4% (338) 31.8% (46) 9.7% (7) 
Current medical treatment 0.8% (82) 20.7% (30) 6.9% (5) 
Ever misused 0.2% (17) 5.3% (8) 2.9% (2) 
Substance use disorder    
Lifetime diagnosis 3.7% (372) 8.3% (12) 19.8% (14) 
Received medical treatment 0.4% (36) 4.0% (6) 5.6% (4) 
Current medical treatment 0.1% (9) 0.8% (1) 1.6% (1) 
Ever misused 0.1% (7) 0.8% (1) 2.9% (2) 
Narcolepsy    
Lifetime diagnosis 1.0% (100) 4.0% (6) 5.2% (4) 
Received medical treatment 0.3% (34) 1.9% (3) 5.2% (4) 
Current medical treatment 0.1% (10) 0.6% (1) 2.0% (1) 
Ever misused 0.03% (3) 0.7% (1) 0 
Note. PCE = pharmacological cognitive enhancement; PME = pharmacological mood enhancement; PNE = 
pharmacological neuroenhancement. 
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Highlights 
 
• Pharmacological neuroenhancement (PNE) as self-medication in health and disease. 
 
• Representative data of employees and students (>10,000) to identify predictors of PNE.  
 
• Drug use for mood enhancement is more prevalent than for cognitive enhancement. 
 
• Mental health, illegal drug use, and stress are important predictors of PNE. 
 
 
*Highlights (for review)
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